BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19GlobeNewsWire • 04/09/20
European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat (BCX7353) to Prevent HAE AttacksGlobeNewsWire • 03/30/20
BioCryst: Take Advantage Of Current Extreme Volatility To Buy At Bargain PricesSeeking Alpha • 03/17/20
BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2GlobeNewsWire • 03/16/20
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/05/20
BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930GlobeNewsWire • 03/05/20
BioCryst Pharmaceuticals: BCX9930 Results In PNH Patients An Important Near-Term CatalystSeeking Alpha • 02/28/20
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% HigherZacks Investment Research • 02/28/20
BioCryst Submits Japanese New Drug Application for Oral, Once Daily BerotralstatGlobeNewsWire • 02/03/20